chloroquine has been researched along with Complications, Parasitic Pregnancy in 109 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chloroquine administered as intermittent therapy did not provide better protection from malaria and related adverse effects compared with intermittent sulfadoxine-pyrimethamine in a setting of high resistance to sulfadoxine-pyrimethamine." | 9.27 | Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial. ( Boudová, S; Divala, TH; Goswami, J; Kanjala, M; Kennedy, J; Laufer, MK; Masonga, R; Mawindo, PM; Mbilizi, Y; Muehlenbachs, A; Mungwira, RG; Muwalo, F; Mvula, P; Ndaferankhande, M; Ndovie, L; Nyirenda, OM; Potter, GE; Tomoka, T; Tsirizani, LE; Wylie, BJ, 2018) |
| "In order to determine the pharmacokinetic disposition of chloroquine (CQ) and its active metabolite, desethylchloroquine (DECQ), when administered as intermittent presumptive treatment in pregnancy (IPTp) for malaria, 30 Papua New Guinean women in the second or third trimester of pregnancy and 30 age-matched nonpregnant women were administered three daily doses of 450 mg CQ (8." | 9.14 | Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. ( Baiwog, F; Davis, TM; Gomorrai, S; Ilett, KF; Karunajeewa, HA; Law, I; Mueller, I; Page-Sharp, M; Rogerson, S; Salman, S; Siba, P, 2010) |
| "The study design was an open randomized control trial comparing anaemia incidence among pregnant women on intermittent presumptive treatment of malaria with SP with those on chloroquine (CQ)." | 9.13 | Efficacy of intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine in preventing anaemia in pregnancy among Nigerian women. ( Abiona, TC; Asa, OO; Fatusi, AO; Ijadunola, KT; Onayade, AA, 2008) |
| "The widespread increase in resistance of Plasmodium falciparum to chloroquine and sulphadoxine-pyrimethamine threatens the use of these drugs for malaria treatment in pregnancy." | 9.12 | Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethamine used alone or in combination for malaria treatment in pregnancy: a randomised trial. ( Browne, E; Bruce, J; Chandramohan, D; Greenwood, B; Randal, A; Tagbor, H, 2006) |
| "A randomized, double-blind, placebo-controlled trial, which compared the effects of three interventions (weekly chloroquine prophylaxis, daily iron and weekly folic-acid supplementation, and case management of malaria) on congenital malaria, maternal haemoglobin (Hb) and foetal outcome, was conducted among primigravidae resident in Hoima district, Uganda." | 9.09 | Chloroquine prophylaxis, iron/folic-acid supplementation or case management of malaria attacks in primigravidae in western Uganda: effects on congenital malaria and infant haemoglobin concentrations. ( Magnussen, P; Ndyomugyenyi, R, 2000) |
| "Two controlled trials of chloroquine prophylaxis during pregnancy were performed, one in Burkina Faso in 1987, on all pregnant women, and the other in Cameroon in 1992, on primigravidae only." | 9.08 | Effect of chloroquine prophylaxis during pregnancy on maternal haematocrit. ( Barro, D; Breart, G; Carnevale, P; Cot, M; Deloron, P; Etya'Ale, D; Fievet, N; le Hesran, JY; Miailhes, P; Roisin, A, 1998) |
| "In West Africa, treatment for the prevention of malaria during pregnancy has recently changed from chloroquine (CQ) prophylaxis to intermittent preventive treatment (IPTp)." | 7.74 | Efficacy of intermittent preventive treatment versus chloroquine prophylaxis to prevent malaria during pregnancy in Benin. ( Briand, V; Cot, M; Denoeud, L; Massougbodji, A, 2008) |
| "In West Africa, administration of chloroquine chemoprophylaxis during pregnancy is common, but little is known about its impact on Plasmodium falciparum infection during pregnancy." | 7.72 | Failure of a chloroquine chemoprophylaxis program to adequately prevent malaria during pregnancy in Koupéla District, Burkina Faso. ( Diarra, A; Konate, A; Moran, AC; Newman, RD; Parise, ME; Sawadogo, R; Sirima, SB; Yameogo, M, 2003) |
| "From the clinical data available, there is no indication that the risk of taking mefloquine in the first trimester of pregnancy is greater than that from any of the other antimalarials studied and the risk is considerably lower than that associated with falciparum malaria." | 7.70 | Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy. ( Edwards, R; Fuchs, E; Kerr, L; Phillips-Howard, PA; Schildknecht, J; Steffen, R; Vanhauwere, B, 1998) |
| "Routine malaria prophylaxis with chloroquine (CQ) is recommended to pregnant semi-immune women in several countries in Africa." | 7.69 | Chloroquine blood concentrations and malaria prophylaxis in Tanzanian women during the second and third trimesters of pregnancy. ( Aden Abdi, Y; Diwan, VK; Ericsson, O; Gustafsson, LL; Kilewo, C; Massele, AY; Rimoy, G; Tomson, G, 1997) |
| "The objective of the study was to determine the efficacy of chloroquine in pregnant women with Plasmodium falciparum parasitemia at therapeutic doses of 25 mg/kg body weight divided over 3 days." | 7.69 | Resistance to chloroquine therapy in pregnant women with malaria parasitemia. ( Ojwang, SB; Oyieke, JB; Rukaria-Kaumbutho, RM, 1996) |
| " In a cohort of pregnant women enrolled at first antenatal clinic visit in rural Malawi, we evaluated reported fever, determined parasitemia, and placed the women on antimalarial regimens containing chloroquine (CQ) or mefloquine (MQ)." | 7.69 | Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. ( Breman, JG; Heymann, DL; Khoromana, CO; Slutsker, L; Steketee, RW; Wirima, JJ, 1996) |
| "Chloroquine was given under observation at a weekly oral dose of 300 mg." | 6.68 | Increase of birth weight following chloroquine chemoprophylaxis during the first pregnancy: results of a randomized trial in Cameroon. ( Breart, G; Cot, M; Esveld, M; Etya'ale, D; Le Hesran, JY; Miailhes, P, 1995) |
| "Chloroquine administered as intermittent therapy did not provide better protection from malaria and related adverse effects compared with intermittent sulfadoxine-pyrimethamine in a setting of high resistance to sulfadoxine-pyrimethamine." | 5.27 | Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial. ( Boudová, S; Divala, TH; Goswami, J; Kanjala, M; Kennedy, J; Laufer, MK; Masonga, R; Mawindo, PM; Mbilizi, Y; Muehlenbachs, A; Mungwira, RG; Muwalo, F; Mvula, P; Ndaferankhande, M; Ndovie, L; Nyirenda, OM; Potter, GE; Tomoka, T; Tsirizani, LE; Wylie, BJ, 2018) |
| "In order to determine the pharmacokinetic disposition of chloroquine (CQ) and its active metabolite, desethylchloroquine (DECQ), when administered as intermittent presumptive treatment in pregnancy (IPTp) for malaria, 30 Papua New Guinean women in the second or third trimester of pregnancy and 30 age-matched nonpregnant women were administered three daily doses of 450 mg CQ (8." | 5.14 | Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. ( Baiwog, F; Davis, TM; Gomorrai, S; Ilett, KF; Karunajeewa, HA; Law, I; Mueller, I; Page-Sharp, M; Rogerson, S; Salman, S; Siba, P, 2010) |
| "The study design was an open randomized control trial comparing anaemia incidence among pregnant women on intermittent presumptive treatment of malaria with SP with those on chloroquine (CQ)." | 5.13 | Efficacy of intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine in preventing anaemia in pregnancy among Nigerian women. ( Abiona, TC; Asa, OO; Fatusi, AO; Ijadunola, KT; Onayade, AA, 2008) |
| "Few studies have documented the effectiveness in west Africa of intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine (SP) in pregnancy." | 5.12 | A comparison of sulfadoxine-pyrimethamine with chloroquine and pyrimethamine for prevention of malaria in pregnant Nigerian women. ( Madaki, JK; Sagay, AS; Thacher, TD; Tukur, IU, 2007) |
| "The widespread increase in resistance of Plasmodium falciparum to chloroquine and sulphadoxine-pyrimethamine threatens the use of these drugs for malaria treatment in pregnancy." | 5.12 | Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethamine used alone or in combination for malaria treatment in pregnancy: a randomised trial. ( Browne, E; Bruce, J; Chandramohan, D; Greenwood, B; Randal, A; Tagbor, H, 2006) |
| "In Mali, IPT with SP appears more efficacious than weekly chloroquine chemoprophylaxis in preventing malaria during pregnancy." | 5.11 | Comparison of intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during pregnancy in Mali. ( Coulibaly, D; Doumbo, O; Doumtabe, D; Kayentao, K; Keita, AS; Kodio, M; Maiga, B; Maiga, H; Mungai, M; Newman, RD; Ongoiba, A; Parise, ME, 2005) |
| " INTERVENTION MEASURES: The intervention measures were intermittent and continuous malaria chemoprophylaxis using chloroquine and proguanil." | 5.09 | Randomised trial of alternative malaria chemoprophylaxis strategies among pregnant women in Kigoma, Tanzania: I. Rationale and design. ( Kabalimu, TK; Mnyika, KS; Mpanju-Shumbusho, W; Rukinisha, K, 2000) |
| "A randomized, double-blind, placebo-controlled trial, which compared the effects of three interventions (weekly chloroquine prophylaxis, daily iron and weekly folic-acid supplementation, and case management of malaria) on congenital malaria, maternal haemoglobin (Hb) and foetal outcome, was conducted among primigravidae resident in Hoima district, Uganda." | 5.09 | Chloroquine prophylaxis, iron/folic-acid supplementation or case management of malaria attacks in primigravidae in western Uganda: effects on congenital malaria and infant haemoglobin concentrations. ( Magnussen, P; Ndyomugyenyi, R, 2000) |
| "Two controlled trials of chloroquine prophylaxis during pregnancy were performed, one in Burkina Faso in 1987, on all pregnant women, and the other in Cameroon in 1992, on primigravidae only." | 5.08 | Effect of chloroquine prophylaxis during pregnancy on maternal haematocrit. ( Barro, D; Breart, G; Carnevale, P; Cot, M; Deloron, P; Etya'Ale, D; Fievet, N; le Hesran, JY; Miailhes, P; Roisin, A, 1998) |
| "In October 1988, a project was implemented for assessing the malaria chemoprophylactic efficacy of weekly chloroquine (CQ) and daily proguanil (PROG) during pregnancy in Muheza-Tanzania." | 5.07 | Malaria in infants whose mothers received chemoprophylaxis: response to amodiaquine therapy. ( de Geus, A; Malle, LN; Mutabingwa, TK; Wernsdorfer, WH, 1992) |
| "The malaria prophylactic effects of chloroquine (CQ), proguanil (PROG), and chloroquine-proguanil combination (CQ+PROG) during pregnancy on maternal haemoglobin levels (Hb), placental malaria, and birth weight were assessed in Muheza, Tanzania." | 5.07 | Malaria chemosuppression in pregnancy. II. Its effect on maternal haemoglobin levels, placental malaria and birth weight. ( de Geus, A; Malle, LN; Mutabingwa, TK; Oosting, J, 1993) |
| "To define an effective and deliverable antimalarial regimen for use during pregnancy, pregnant women at highest risk of malaria (those in their first or second pregnancy) in an area of Malawi with high transmission of chloroquine (CQ)-resistant Plasmodium falciparum were placed on CQ and/or sulfadoxine-pyrimethamine (SP)." | 5.07 | The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. ( Chitsulo, L; Kazembe, P; Macheso, A; Schultz, LJ; Steketee, RW; Wirima, JJ, 1994) |
| "The antimalarial drugs chloroquine (CQ) and hydroxychloroquine (HCQ) have been used for decades to treat rheumatic diseases." | 4.87 | Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. ( Koren, G; Osadchy, A; Ratnapalan, T, 2011) |
| "Alternative drugs to chloroquine are required to prevent the deleterious effects of malaria in pregnancy." | 4.79 | The safety of antimalarial drugs in pregnancy. ( Phillips-Howard, PA; Wood, D, 1996) |
| "Using data from a trial of medication to prevent malaria in pregnancy that randomized 600 women to receive chloroquine or sulfadoxine-pyrimethamine during pregnancy, we conducted a NCC study assessing the role of prospectively collected AEs, as exposure of interest, on treatment non-adherence and study non-completion." | 4.12 | Effect of adverse events on non-adherence and study non-completion in malaria chemoprevention during pregnancy trial: A nested case control study. ( Chirwa, T; Divala, T; Kazembe, L; Laufer, MK; Mathanga, D; Mukaka, M; Patson, N; Peterson, I, 2022) |
| " The questionnaire elicited information on their: knowledge about malaria, attitude, chemotherapy and chemoprophylaxis using pyrimethamine, chloroquine proguanil as well as IPTp with sulphadoxine-pyrimethamine (SP)." | 3.78 | Patterns of case management and chemoprevention for malaria-in-pregnancy by public and private sector health providers in Enugu state, Nigeria. ( Onwujekwe, O; Onwujekwe, OC; Shu, E; Soremekun, RO; Uzochukwu, B, 2012) |
| " Chloroquine or hydroxychloroquine are considered safe to use in all trimesters of pregnancy." | 3.77 | Prophylactic use of antimalarials during pregnancy. ( Bozzo, P; Einarson, A; Irvine, MH, 2011) |
| "Questioning was centred by frequency order on: the pregnancy antecedents (65%), the chloroquine direction for use (34." | 3.74 | [Quality of malaria prevention during prenatal consultations in Niakhar (Senegal)]. ( Faye, A; Ndiaye, P; Tal, DA, 2007) |
| "In West Africa, treatment for the prevention of malaria during pregnancy has recently changed from chloroquine (CQ) prophylaxis to intermittent preventive treatment (IPTp)." | 3.74 | Efficacy of intermittent preventive treatment versus chloroquine prophylaxis to prevent malaria during pregnancy in Benin. ( Briand, V; Cot, M; Denoeud, L; Massougbodji, A, 2008) |
| "We compared the pharmacokinetics of chloroquine in pregnant and nonpregnant women treated for Plasmodium vivax malaria." | 3.74 | Chloroquine pharmacokinetics in pregnant and nonpregnant women with vivax malaria. ( Fernandez, C; Greenwood, BM; Lee, SJ; McGready, R; Nosten, F; Paw, MK; Singhasivanon, P; Stepniewska, K; Thwai, KL; Viladpai-nguen, SJ; Villegas, L; White, NJ, 2008) |
| "In Papua New Guinea, chloroquine (CQ; 25 mg base kg(-1)) is recommended for prophylaxis of malaria during pregnancy, and at the Alexishafen Health Centre women are routinely prescribed CQ at the time of delivery." | 3.74 | Transfer of chloroquine and desethylchloroquine across the placenta and into milk in Melanesian mothers. ( Baiwog, F; Davis, TM; Gomorrai, S; Hackett, LP; Ilett, KF; Karunajeewa, HA; Law, I; Mueller, I; Page-Sharp, M, 2008) |
| "Several factors appear to have accelerated the process: (1) recognition of the extent of the problem of malaria during pregnancy and its adverse consequences; (2) a clear, evidence-based program strategy strongly articulated by an important multilateral organization (World Health Organization); (3) subregionally generated evidence to support the proposed strategy; (4) a subregional forum for dissemination of data and discussion regarding the proposed policy changes; (5) widespread availability of the proposed intervention drug (sulfadoxine-pyrimethamine); (6) technical support from reputable and respected institutions in drafting new policies and planning for implementation; (7) donor support for pilot experiences in integrating proposed policy change into a package of preventive services; and (8) financial support for scaling up the proposed interventions." | 3.73 | Prevention of malaria during pregnancy in West Africa: policy change and the power of subregional action. ( Benga-De, E; Doumbo, O; Faye, O; Gaye, O; Kayentao, K; Lo, Y; Moran, AC; Moreira, PM; Newman, RD; Parise, ME; Steketee, RW; Yameogo, M, 2006) |
| "In West Africa, administration of chloroquine chemoprophylaxis during pregnancy is common, but little is known about its impact on Plasmodium falciparum infection during pregnancy." | 3.72 | Failure of a chloroquine chemoprophylaxis program to adequately prevent malaria during pregnancy in Koupéla District, Burkina Faso. ( Diarra, A; Konate, A; Moran, AC; Newman, RD; Parise, ME; Sawadogo, R; Sirima, SB; Yameogo, M, 2003) |
| "Routine chloroquine prophylaxis in pregnancy is useful in reducing anemia at childbirth in malaria-endemic regions." | 3.71 | Malaria prophylaxis and the reduction of anemia at childbirth. ( Addae, V; Asare, K; Geelhoed, DW; Schagen van Leeuwen, JH; van Roosmalen, J; Visser, LE, 2001) |
| "1%) took anti-malaria prophylaxis (chloroquine) in the index pregnancy, and 136 (58." | 3.70 | Effect of chloroquine prophylaxis on birthweight and malaria parasite load among pregnant women delivering in a regional hospital in Cameroon. ( Ratard, R; Salihu, HM; Tchuinguem, G, 2000) |
| "From the clinical data available, there is no indication that the risk of taking mefloquine in the first trimester of pregnancy is greater than that from any of the other antimalarials studied and the risk is considerably lower than that associated with falciparum malaria." | 3.70 | Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy. ( Edwards, R; Fuchs, E; Kerr, L; Phillips-Howard, PA; Schildknecht, J; Steffen, R; Vanhauwere, B, 1998) |
| "While there is broad evidence for the adverse effects of Plasmodium falciparum infection in pregnancy, and the World Health Organization recommends preventive strategies, there is markedly reduced efficacy in sub-Saharan Africa of the most widely available, affordable and used antimalarial drug for chemoprophylaxis-chloroquine (CQ)." | 3.69 | The effect of malaria and malaria prevention in pregnancy on offspring birthweight, prematurity, and intrauterine growth retardation in rural Malawi. ( Breman, JG; Heymann, DL; Hightower, AW; Slutsker, L; Steketee, RW; Wirima, JJ, 1996) |
| " In a cohort of pregnant women enrolled at first antenatal clinic visit in rural Malawi, we evaluated reported fever, determined parasitemia, and placed the women on antimalarial regimens containing chloroquine (CQ) or mefloquine (MQ)." | 3.69 | Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. ( Breman, JG; Heymann, DL; Khoromana, CO; Slutsker, L; Steketee, RW; Wirima, JJ, 1996) |
| "The objective of the study was to determine the efficacy of chloroquine in pregnant women with Plasmodium falciparum parasitemia at therapeutic doses of 25 mg/kg body weight divided over 3 days." | 3.69 | Resistance to chloroquine therapy in pregnant women with malaria parasitemia. ( Ojwang, SB; Oyieke, JB; Rukaria-Kaumbutho, RM, 1996) |
| "Routine malaria prophylaxis with chloroquine (CQ) is recommended to pregnant semi-immune women in several countries in Africa." | 3.69 | Chloroquine blood concentrations and malaria prophylaxis in Tanzanian women during the second and third trimesters of pregnancy. ( Aden Abdi, Y; Diwan, VK; Ericsson, O; Gustafsson, LL; Kilewo, C; Massele, AY; Rimoy, G; Tomson, G, 1997) |
| " Chloroquine, quinine and pyrimethamine, administered after macrogametocytes of Plasmodium falciparum had been found in the blood smear, eliminated the parasites from the peripheral blood, but respiratory failure and treatment-resistant pneumonia occurred, leading to the adult respiratory distress syndrome (Morel stage 4)." | 3.68 | [Acute respiratory failure in tropical malaria during pregnancy. Successful treatment using extracorporeal CO2 elimination]. ( Benzing, A; Dippold, W; Grundmann, H; Knolle, P; Meyer zum Büschenfelde, KH; Neurath, M, 1993) |
| "Intermittent preventive treatment in pregnancy has not been evaluated outside of Africa." | 2.80 | Sulphadoxine-pyrimethamine plus azithromycin for the prevention of low birthweight in Papua New Guinea: a randomised controlled trial. ( Bardaji, A; Betuela, I; Hanieh, S; Kongs, C; Lufele, E; Menendez, C; Mueller, I; Ome-Kaius, M; Robinson, LJ; Rogerson, SJ; Rosanas-Urgell, A; Samol, P; Schofield, L; Siba, P; Singirok, D; Suen, CS; Sui, D; Umbers, AJ; Unger, HW; Wangnapi, RA; Wapling, J, 2015) |
| "Birth weight was analyzed through multivariate linear and logistic regressions." | 2.73 | The importance of the period of malarial infection during pregnancy on birth weight in tropical Africa. ( Barro, D; Cot, M; Cottrell, G; Mary, JY, 2007) |
| "The strategy of intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) was also addressed." | 2.72 | Drug treatment and prevention of malaria in pregnancy: a critical review of the guidelines. ( Al Khaja, KAJ; Sequeira, RP, 2021) |
| "Chloroquine was given under observation at a weekly oral dose of 300 mg." | 2.68 | Increase of birth weight following chloroquine chemoprophylaxis during the first pregnancy: results of a randomized trial in Cameroon. ( Breart, G; Cot, M; Esveld, M; Etya'ale, D; Le Hesran, JY; Miailhes, P, 1995) |
| " All drug dosing was performed under supervision by the study team, making this an evaluation of intervention efficacy (excluding the role of patient compliance)." | 2.68 | Objectives and methodology in a study of malaria treatment and prevention in pregnancy in rural Malawi: The Mangochi Malaria Research Project. ( Breman, JG; Heymann, DL; Khoromana, CO; Slutsker, WL; Steketee, RW; Wirima, JJ, 1996) |
| "As pregnancy has been shown to alter the pharmacokinetics of many medications, the efficacy and safety of antimalarial drug regimens may be compromised in pregnant women." | 2.47 | Pharmacokinetics of antimalarials in pregnancy: a systematic review. ( Ensom, MH; Wilby, KJ, 2011) |
| "Severe malaria is a multisystem disease affecting particularly the central nervous system (causing coma and convulsions), the kidneys (resulting in acute tubular necrosis), and the liver (contributing to lactic acidosis and hypoglycaemia)." | 2.38 | Clinical malaria in the tropics. ( Pukrittayakamee, S; White, NJ, 1993) |
| "We compare recurrence rates observed after primary P." | 1.56 | Quantifying and preventing Plasmodium vivax recurrences in primaquine-untreated pregnant women: An observational and modeling study in Brazil. ( Corder, RM; Davenport, MP; de Lima, ACP; Docken, SS; Ferreira, MU; Khoury, DS, 2020) |
| "Chloroquine [27." | 1.38 | Determinants of intermittent preventive treatment of malaria during pregnancy (IPTp) utilization in a rural town in Western Nigeria. ( Amoran, OE; Ariba, AA; Iyaniwura, CA, 2012) |
| "Genotyping confirmed that recrudescence after malaria treatment occurred in 7 (21%) out of 33 pregnant women with consecutive episodes during the same pregnancy (time range between recrudescent episodes: 14 to 187 days)." | 1.35 | Sub-microscopic infections and long-term recrudescence of Plasmodium falciparum in Mozambican pregnant women. ( Alonso, PL; Aponte, JJ; Bardají, A; Cisteró, P; Mandomando, I; Mayor, A; Menéndez, C; Puyol, L; Sanz, S; Serra-Casas, E; Sigauque, B, 2009) |
| "Sulfadoxine-pyrimethamine was significantly more commonly prescribed by primary health care providers than in other levels of care (chi2 = 15." | 1.34 | Perception and practice of malaria prophylaxis in pregnancy among health care providers in Ibadan. ( Fawole, AO; Onyeaso, NC, 2007) |
| "Chloroquine resistance was seen in 23% of the cases." | 1.32 | Forest malaria in Chhindwara, Madhya Pradesh, central India: a case study in a tribal community. ( Chand, SK; Mishra, AK; Shukla, MM; Singh, N, 2003) |
| "Chloroquine was the most widely used antimalarial." | 1.31 | [Malaria and pregnancy: attitude of health care personnel during prenatal care in Cotonou, Benin]. ( Akogbeto, M; Nahum, A, 2000) |
| " The dose-response relationship between the severity of parasitaemia and the risk of being anaemic (P < 0." | 1.31 | Weekly chloroquine prophylaxis and the effect on maternal haemoglobin status at delivery. ( Bosny, JP; Dagne, G; Naik, EG; Salihu, HM; Tchuinguem, G, 2002) |
| "We conclude that malaria is the major cause of anemia in pregnancy in this region." | 1.30 | Seasonality, malaria, and impact of prophylaxis in a West African village I. Effect of anemia in pregnancy. ( Bouvier, P; Breslow, N; Delley, V; Dembele, HK; Doumbo, O; Kouriba, B; Mauris, A; Picquet, M; Robert, CF; Rougemont, A, 1997) |
| " In nine of 13 patients who received prophylaxis, there was inadequate dosing or poor compliance." | 1.28 | Imported malaria in the Bronx: review of 51 cases recorded from 1986 to 1991. ( Froude, JR; Tanowitz, HB; Weiss, LM; Wittner, M, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 47 (43.12) | 18.2507 |
| 2000's | 40 (36.70) | 29.6817 |
| 2010's | 19 (17.43) | 24.3611 |
| 2020's | 3 (2.75) | 2.80 |
| Authors | Studies |
|---|---|
| Karunajeewa, HA | 2 |
| Salman, S | 1 |
| Mueller, I | 4 |
| Baiwog, F | 2 |
| Gomorrai, S | 2 |
| Law, I | 2 |
| Page-Sharp, M | 2 |
| Rogerson, S | 1 |
| Siba, P | 2 |
| Ilett, KF | 2 |
| Davis, TM | 2 |
| Patson, N | 1 |
| Mukaka, M | 1 |
| Peterson, I | 1 |
| Divala, T | 2 |
| Kazembe, L | 1 |
| Mathanga, D | 1 |
| Laufer, MK | 3 |
| Chirwa, T | 1 |
| Corder, RM | 1 |
| de Lima, ACP | 1 |
| Khoury, DS | 1 |
| Docken, SS | 1 |
| Davenport, MP | 1 |
| Ferreira, MU | 1 |
| Al Khaja, KAJ | 1 |
| Sequeira, RP | 1 |
| Boudová, S | 2 |
| Mungwira, R | 1 |
| Mawindo, P | 1 |
| Tomoka, T | 2 |
| Divala, TH | 1 |
| Mungwira, RG | 1 |
| Mawindo, PM | 1 |
| Nyirenda, OM | 1 |
| Kanjala, M | 1 |
| Ndaferankhande, M | 1 |
| Tsirizani, LE | 1 |
| Masonga, R | 1 |
| Muwalo, F | 1 |
| Potter, GE | 1 |
| Kennedy, J | 1 |
| Goswami, J | 1 |
| Wylie, BJ | 1 |
| Muehlenbachs, A | 1 |
| Ndovie, L | 1 |
| Mvula, P | 1 |
| Mbilizi, Y | 1 |
| Kain, KC | 1 |
| Doumbo, S | 1 |
| Ongoiba, OA | 1 |
| Doumtabé, D | 2 |
| Dara, A | 1 |
| Ouologuem, TD | 1 |
| Kayentao, K | 4 |
| Djimdé, A | 1 |
| Traoré, B | 2 |
| Doumbo, OK | 2 |
| Sharma, L | 1 |
| Shukla, G | 1 |
| Rabiu, KA | 1 |
| Davies, NO | 1 |
| Nzeribe-Abangwu, UO | 1 |
| Adewunmi, AA | 1 |
| Akinlusi, FM | 1 |
| Akinola, OI | 1 |
| Ogundele, SO | 1 |
| Unger, HW | 2 |
| Ome-Kaius, M | 1 |
| Wangnapi, RA | 1 |
| Umbers, AJ | 1 |
| Hanieh, S | 1 |
| Suen, CS | 1 |
| Robinson, LJ | 1 |
| Rosanas-Urgell, A | 1 |
| Wapling, J | 1 |
| Lufele, E | 1 |
| Kongs, C | 1 |
| Samol, P | 1 |
| Sui, D | 1 |
| Singirok, D | 1 |
| Bardaji, A | 2 |
| Schofield, L | 1 |
| Menendez, C | 2 |
| Betuela, I | 1 |
| Rogerson, SJ | 2 |
| Teo, A | 1 |
| Hasang, W | 1 |
| Randall, LM | 1 |
| Siba, PM | 1 |
| Brown, GV | 1 |
| Al Hammadi, A | 1 |
| Mitchell, M | 1 |
| Abraham, GM | 1 |
| Wang, JP | 1 |
| Lee, SJ | 1 |
| McGready, R | 2 |
| Fernandez, C | 1 |
| Stepniewska, K | 1 |
| Paw, MK | 1 |
| Viladpai-nguen, SJ | 1 |
| Thwai, KL | 1 |
| Villegas, L | 1 |
| Singhasivanon, P | 1 |
| Greenwood, BM | 1 |
| White, NJ | 2 |
| Nosten, F | 2 |
| Briand, V | 2 |
| Denoeud, L | 1 |
| Massougbodji, A | 2 |
| Cot, M | 5 |
| Chico, RM | 1 |
| Pittrof, R | 1 |
| Greenwood, B | 3 |
| Chandramohan, D | 3 |
| Ndiaye, P | 1 |
| Faye, A | 1 |
| Tal, DA | 1 |
| Mayor, A | 1 |
| Serra-Casas, E | 1 |
| Sanz, S | 1 |
| Puyol, L | 1 |
| Cisteró, P | 1 |
| Sigauque, B | 1 |
| Mandomando, I | 1 |
| Aponte, JJ | 1 |
| Alonso, PL | 1 |
| Del Punta, V | 1 |
| Gulletta, M | 1 |
| Matteelli, A | 1 |
| Spinoni, V | 1 |
| Regazzoli, A | 1 |
| Castelli, F | 1 |
| Onyeaso, NC | 1 |
| Fawole, AO | 1 |
| Le Port, A | 1 |
| Cottrell, G | 2 |
| Dechavanne, C | 1 |
| Bouraima, A | 1 |
| Guerra, J | 1 |
| Choudat, I | 1 |
| Fayomi, B | 1 |
| Migot-Nabias, F | 1 |
| Garcia, A | 1 |
| Tongo, OO | 1 |
| Orimadegun, AE | 1 |
| Akinyinka, OO | 1 |
| Wilby, KJ | 1 |
| Ensom, MH | 1 |
| Osadchy, A | 1 |
| Ratnapalan, T | 1 |
| Koren, G | 1 |
| Irvine, MH | 1 |
| Einarson, A | 1 |
| Bozzo, P | 1 |
| Onwujekwe, OC | 1 |
| Soremekun, RO | 1 |
| Uzochukwu, B | 1 |
| Shu, E | 1 |
| Onwujekwe, O | 1 |
| Schlagenhauf, P | 1 |
| Petersen, E | 1 |
| Amoran, OE | 1 |
| Ariba, AA | 1 |
| Iyaniwura, CA | 1 |
| Fowkes, FJ | 1 |
| Cross, NJ | 1 |
| Hommel, M | 1 |
| Simpson, JA | 1 |
| Elliott, SR | 1 |
| Richards, JS | 1 |
| Lackovic, K | 1 |
| Viladpai-Nguen, J | 1 |
| Narum, D | 1 |
| Tsuboi, T | 1 |
| Anders, RF | 1 |
| Beeson, JG | 1 |
| Sirima, SB | 1 |
| Sawadogo, R | 1 |
| Moran, AC | 2 |
| Konate, A | 1 |
| Diarra, A | 1 |
| Yameogo, M | 2 |
| Parise, ME | 3 |
| Newman, RD | 3 |
| Singh, N | 2 |
| Mishra, AK | 1 |
| Shukla, MM | 1 |
| Chand, SK | 2 |
| Mugisho, E | 1 |
| Dramaix, M | 1 |
| Porignon, D | 1 |
| Mouafo, JB | 1 |
| Vanbellinghen, AM | 1 |
| Hennart, P | 1 |
| Meuris, S | 1 |
| Bouyou-Akotet, MK | 1 |
| Ionete-Collard, DE | 1 |
| Mabika-Manfoumbi, M | 1 |
| Kendjo, E | 1 |
| Matsiegui, PB | 1 |
| Mavoungou, E | 1 |
| Kombila, M | 1 |
| Martínez-Espinosa, FE | 1 |
| Daniel-Ribeiro, CT | 1 |
| Alecrim, WD | 1 |
| Oduola, OO | 1 |
| Happi, TC | 1 |
| Gbotosho, GO | 1 |
| Ogundahunsi, OA | 1 |
| Falade, CO | 1 |
| Akinboye, DO | 1 |
| Sowunmi, A | 1 |
| Oduola, AM | 1 |
| Kodio, M | 2 |
| Maiga, H | 1 |
| Ongoiba, A | 1 |
| Coulibaly, D | 2 |
| Keita, AS | 2 |
| Maiga, B | 2 |
| Mungai, M | 2 |
| Doumbo, O | 4 |
| Adam, I | 1 |
| Ali, DM | 1 |
| Noureldien, W | 1 |
| Elbashir, MI | 1 |
| Nyunt, M | 1 |
| Pisciotta, J | 1 |
| Feldman, AB | 1 |
| Thuma, P | 1 |
| Scholl, PF | 1 |
| Demirev, PA | 1 |
| Lin, JS | 1 |
| Shi, L | 1 |
| Kumar, N | 1 |
| Sullivan, DJ | 1 |
| Botelho-Nevers, E | 1 |
| Laurencin, S | 1 |
| Delmont, J | 1 |
| Parola, P | 1 |
| Mehlotra, RK | 1 |
| Mattera, G | 1 |
| Bhatia, K | 1 |
| Reeder, JC | 1 |
| Stoneking, M | 1 |
| Zimmerman, PA | 1 |
| Benga-De, E | 1 |
| Gaye, O | 3 |
| Faye, O | 2 |
| Lo, Y | 1 |
| Moreira, PM | 1 |
| Steketee, RW | 10 |
| Coulibaly, SO | 1 |
| Nezien, D | 1 |
| Traoré, S | 1 |
| Koné, B | 1 |
| Magnussen, P | 2 |
| Enato, EF | 1 |
| Okhamafe, AO | 1 |
| Tagbor, H | 2 |
| Bruce, J | 2 |
| Browne, E | 2 |
| Randal, A | 1 |
| Tinto, H | 1 |
| Ouédraogo, JB | 1 |
| Zongo, I | 1 |
| van Overmeir, C | 1 |
| van Marck, E | 1 |
| Guiguemdé, TR | 1 |
| D'Alessandro, U | 1 |
| Valecha, N | 2 |
| Bhatia, S | 1 |
| Mehta, S | 1 |
| Biswas, S | 1 |
| Dash, AP | 1 |
| Mary, JY | 1 |
| Barro, D | 2 |
| Parise, M | 1 |
| Tukur, IU | 1 |
| Thacher, TD | 1 |
| Sagay, AS | 1 |
| Madaki, JK | 1 |
| Ord, R | 1 |
| Randall, A | 1 |
| Coldren, RL | 1 |
| Jongsakul, K | 1 |
| Vayakornvichit, S | 1 |
| Noedl, H | 1 |
| Fukudas, MM | 1 |
| Asa, OO | 1 |
| Onayade, AA | 1 |
| Fatusi, AO | 1 |
| Ijadunola, KT | 1 |
| Abiona, TC | 1 |
| Hackett, LP | 1 |
| Wetsteyn, JC | 1 |
| de Geus, A | 8 |
| Mnyika, KS | 2 |
| Kabalimu, TK | 2 |
| Lugoe, WL | 1 |
| Astagneau, P | 1 |
| Wirima, JJ | 10 |
| Khoromana, CO | 4 |
| Millet, P | 1 |
| Helitzer-Allen, DL | 2 |
| Macheso, A | 3 |
| Wirima, J | 1 |
| Kendall, C | 1 |
| Schultz, LJ | 3 |
| Chitsulo, L | 3 |
| Brain, SD | 1 |
| de Silva, HA | 1 |
| Walker, B | 1 |
| Kazembe, P | 2 |
| Pertet, AM | 1 |
| Mutabingwa, TK | 7 |
| Eling, WM | 3 |
| Kitinya, JN | 1 |
| Malle, LN | 7 |
| Meuwissen, JH | 3 |
| Reuben, R | 1 |
| Verhave, JP | 2 |
| Neurath, M | 1 |
| Benzing, A | 1 |
| Knolle, P | 1 |
| Grundmann, H | 1 |
| Dippold, W | 1 |
| Meyer zum Büschenfelde, KH | 1 |
| Pukrittayakamee, S | 1 |
| McFarland, DA | 1 |
| Macheso, AP | 1 |
| Nyirjesy, P | 1 |
| Kavasya, T | 1 |
| Axelrod, P | 1 |
| Fischer, PR | 1 |
| Robson, JM | 1 |
| Conroy, D | 1 |
| Cremin, JM | 1 |
| Hannaford, R | 1 |
| Dunn, TA | 1 |
| Oosting, J | 2 |
| Okoyeh, JN | 1 |
| Lege-Oguntoye, L | 1 |
| Emembolu, JO | 1 |
| Sarki, U | 1 |
| Slotboom, AB | 1 |
| Le Hesran, JY | 2 |
| Miailhes, P | 2 |
| Esveld, M | 1 |
| Etya'ale, D | 2 |
| Breart, G | 2 |
| Slutsker, L | 4 |
| Breman, JG | 5 |
| Heymann, DL | 5 |
| Roberts, JM | 1 |
| Hightower, AW | 1 |
| Slutsker, WL | 1 |
| Rukaria-Kaumbutho, RM | 1 |
| Ojwang, SB | 1 |
| Oyieke, JB | 1 |
| Phillips-Howard, PA | 3 |
| Wood, D | 1 |
| Fontes, CJ | 1 |
| Munhoz, S | 1 |
| Bouvier, P | 2 |
| Breslow, N | 2 |
| Robert, CF | 2 |
| Mauris, A | 2 |
| Picquet, M | 2 |
| Kouriba, B | 1 |
| Dembele, HK | 2 |
| Delley, V | 2 |
| Rougemont, A | 2 |
| Dolo, A | 1 |
| Massele, AY | 1 |
| Kilewo, C | 1 |
| Aden Abdi, Y | 1 |
| Tomson, G | 1 |
| Diwan, VK | 1 |
| Ericsson, O | 1 |
| Rimoy, G | 1 |
| Gustafsson, LL | 1 |
| Elzubier, AG | 1 |
| Ansari, EH | 1 |
| el Nour, MH | 1 |
| Bella, H | 1 |
| Roisin, A | 1 |
| Fievet, N | 2 |
| Deloron, P | 2 |
| Carnevale, P | 1 |
| Saxena, A | 1 |
| Sharma, VP | 1 |
| Steffen, R | 1 |
| Kerr, L | 1 |
| Vanhauwere, B | 1 |
| Schildknecht, J | 1 |
| Fuchs, E | 1 |
| Edwards, R | 1 |
| Diallo, S | 2 |
| Bah, IB | 2 |
| Dieng, Y | 2 |
| Ndir, O | 1 |
| Ba, FD | 1 |
| Diop, BM | 1 |
| Dieng, T | 2 |
| Mar, M | 1 |
| Diop, M | 1 |
| N'Dir, O | 1 |
| Hovette, P | 1 |
| Camara, P | 1 |
| Burgel, PR | 1 |
| Mbaye, PS | 1 |
| Sane, M | 1 |
| Klotz, F | 1 |
| Botella de Maglia, J | 1 |
| Espacio Casanovas, A | 1 |
| Viraraghavan, R | 1 |
| Jantausch, B | 1 |
| Rukinisha, K | 1 |
| Mpanju-Shumbusho, W | 1 |
| Salihu, HM | 2 |
| Tchuinguem, G | 2 |
| Ratard, R | 1 |
| Ndyomugyenyi, R | 1 |
| Nahum, A | 1 |
| Akogbeto, M | 1 |
| Staalsoe, T | 1 |
| Megnekou, R | 1 |
| Ricke, CH | 1 |
| Zornig, HD | 1 |
| Leke, R | 1 |
| Taylor, DW | 1 |
| Hviid, L | 1 |
| Geelhoed, DW | 1 |
| Visser, LE | 1 |
| Addae, V | 1 |
| Asare, K | 1 |
| Schagen van Leeuwen, JH | 1 |
| van Roosmalen, J | 1 |
| Browne, EN | 1 |
| Maude, GH | 1 |
| Binka, FN | 1 |
| Mockenhaupt, FP | 1 |
| Eggelte, TA | 1 |
| Till, H | 1 |
| Bienzle, U | 1 |
| Naik, EG | 1 |
| Bosny, JP | 1 |
| Dagne, G | 1 |
| Wernsdorfer, WH | 1 |
| Toan, NG | 1 |
| Froude, JR | 1 |
| Weiss, LM | 1 |
| Tanowitz, HB | 1 |
| Wittner, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Controlled Clinical Trial of Chloroquine as Chemoprophylaxis Versus Intermittent Preventive Therapy to Prevent Malaria in Pregnancy in Malawi[NCT01443130] | Phase 3 | 900 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity[NCT05757167] | Phase 4 | 2,500 participants (Anticipated) | Interventional | 2023-11-06 | Recruiting | ||
| Intermittent Preventive Treatment With Azithromycin-containing Regimens for the Prevention of Malarial Infections and Anaemia and the Control of Sexually Transmitted Infections in Pregnant Women in Papua New Guinea[NCT01136850] | Phase 3 | 2,793 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Intermittent Preventive Treatment During Pregnancy in Benin: a Randomized, Open, and Equivalent Trial Comparing Sulfadoxine-Pyrimethamine With Mefloquine[NCT00274235] | Phase 3 | 1,600 participants (Anticipated) | Interventional | 2005-07-31 | Completed | ||
| Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss ,Double Blinded Randomized Controlled Trial .[NCT05237843] | Phase 1 | 70 participants (Anticipated) | Interventional | 2022-03-01 | Not yet recruiting | ||
| New Tools for Diagnosis and Management of Febrile Illness in Travelers to the Tropics: a Cohort Study- JOKA I[NCT02900079] | 0 participants (Actual) | Observational [Patient Registry] | 2023-07-01 | Withdrawn (stopped due to delays in obtaining study materials) | |||
| A Randomised Double Blind Clinical Trial of Amodiaquine (AQ) and Sulphadoxine-pyrimethamine (SP) Used Singly and in Combination (AQ+SP) Compared With Chloroquine (CQ) in the Treatment of Falciparum Malaria Infection in Pregnancy[NCT00131703] | Phase 3 | 900 participants | Interventional | 2003-03-31 | Completed | ||
| A Comparative Study of Mefloquine and Sulphadoxine-pyrimethamine as Prophylaxis Against Malaria in Pregnant Human Immunodeficiency Virus Positive Patients[NCT02524444] | Phase 1 | 142 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers[NCT00367380] | Phase 2 | 18 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Maternal participants were followed to outcome of the pregnancy. This outcome measure provides the number of placental malaria infections in maternal subjects diagnosed by the presence of parasites and/or pigment on histological section or molecular evidence of infection (PCR). (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment
| Intervention | percentage of participants (Number) |
|---|---|
| Maternal Chloroquine Prophylaxis | 3.09 |
| Maternal Chloroquine IPT | 3.16 |
| Maternal SP IPT | 4.74 |
Maternal participants were followed to outcome of the pregnancy. Clinical malaria is defined as malaria infection at any parasite density with associated symptoms including at least one of the following: objective fever measured at the clinic, history of fever in the past 48 hours or other symptoms in the last 48 hours including: headache, myalgia, vomiting, or weakness. (NCT01443130)
Timeframe: Enrollment to delivery (approximately 12-36 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Maternal Chloroquine Prophylaxis | 0.67 |
| Maternal Chloroquine IPT | 1.33 |
| Maternal SP IPT | 3.00 |
Maternal participants were followed to outcome of the pregnancy. This outcome measure provides the number of positive for malaria cord blood smear and cord PCR results in maternal subjects based on the results of the thick smear and PCR from the cord blood sample. (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment
| Intervention | percentage of participants (Number) |
|---|---|
| Maternal Chloroquine Prophylaxis | 1.95 |
| Maternal Chloroquine IPT | 2.78 |
| Maternal SP IPT | 0.80 |
Infants were followed from the time of delivery until 14 weeks of age. This outcome measure provides the incidence of infants with IUGR at delivery. IUGR is defined as weight below the 10th percentile for gestational age based on the World Health Organization (WHO) fetal growth curve. This classification is supported by literature resulting from the INTERGROWTH-21st Project; José Villar. (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment
| Intervention | percentage of participants (Number) |
|---|---|
| Infant Chloroquine Prophylaxis | 16.54 |
| Infant Chloroquine IPT | 18.01 |
| Infant SP IPT | 20.80 |
Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of infants whose birthweight was less than 2500 grams. (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment
| Intervention | percentage of infants (Number) |
|---|---|
| Infant Chloroquine Prophylaxis | 15.59 |
| Infant Chloroquine IPT | 10.98 |
| Infant SP IPT | 12.11 |
Maternal participants were followed to outcome of the pregnancy. This outcome measure provides the number of malaria infection episodes measured by positive parasitemia in maternal subjects. (NCT01443130)
Timeframe: Enrollment to delivery (approximately 12-36 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Maternal Chloroquine Prophylaxis | 0.67 |
| Maternal Chloroquine IPT | 1.67 |
| Maternal SP IPT | 3.00 |
Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of anemia among maternal participants during pregnancy . Anemia is defined as having a hemoglobin value less than 10 grams/deciliter (gm/dL). (NCT01443130)
Timeframe: From enrollment until delivery, approximately 12-36 weeks
| Intervention | percentage of maternal participants (Number) |
|---|---|
| Maternal Chloroquine Prophylaxis | 18.3 |
| Maternal Chloroquine IPT | 23.7 |
| Maternal SP IPT | 22.0 |
Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of severe anemia among maternal participants during pregnancy. Severe anemia is defined as having a hemoglobin value less than 7 gm/dl. (NCT01443130)
Timeframe: From enrollment until delivery, approximately 12-36 weeks
| Intervention | percentage of maternal participants (Number) |
|---|---|
| Maternal Chloroquine Prophylaxis | 0.0 |
| Maternal Chloroquine IPT | 0.3 |
| Maternal SP IPT | 0.3 |
Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of participants' deliveries whose outcome was miscarriage, defined as an infant delivered without any signs of life at less than 28 weeks of gestation. (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment
| Intervention | percentage of pregnancies (Number) |
|---|---|
| Maternal Chloroquine Prophylaxis | 0.33 |
| Maternal Chloroquine IPT | 0.67 |
| Maternal SP IPT | 1.00 |
Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of malaria infection in the placenta based on diagnosis by positive placental impression smear results. (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment
| Intervention | percentage of placentas (Number) |
|---|---|
| Maternal Chloroquine Prophylaxis | 0 |
| Maternal Chloroquine IPT | 0 |
| Maternal SP IPT | 0.40 |
The placenta was collected at the time of delivery for examination by histology to determine malaria infection. Malaria infection was concluded if histology identified parasites or malaria pigment in the placental tissue. (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment
| Intervention | percentage of pregnancies (Number) |
|---|---|
| Maternal Chloroquine Prophylaxis | 11.58 |
| Maternal Chloroquine IPT | 15.42 |
| Maternal SP IPT | 15.42 |
Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of participants' deliveries whose outcome was preterm delivery, defined as delivery less than 37 weeks of gestation. The outcome of the delivery was not considered, and could have been live birth, stillbirth, or miscarriage. (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment
| Intervention | percentage of deliveries (Number) |
|---|---|
| Maternal Chloroquine Prophylaxis | 8.46 |
| Maternal Chloroquine IPT | 9.89 |
| Maternal SP IPT | 6.84 |
Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of participants' deliveries whose outcome was stillbirth, defined as an infant born without any signs of life at 28 weeks or greater of gestation. (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment
| Intervention | percentage of deliveries (Number) |
|---|---|
| Maternal Chloroquine Prophylaxis | 1.10 |
| Maternal Chloroquine IPT | 0.37 |
| Maternal SP IPT | 1.90 |
Infants were followed from the time of delivery until 14 weeks of age. This outcome measure provides the incidence of infants who died within 14 weeks of delivery. (NCT01443130)
Timeframe: For 14 weeks after delivery.
| Intervention | percentage of infants (Number) |
|---|---|
| Infant Chloroquine Prophylaxis | 2.22 |
| Infant Chloroquine IPT | 3.65 |
| Infant SP IPT | 3.09 |
Thick blood smear was performed to patients daily on days 7 to 23, and every other day until day 29. Any prove of P. vivax infection was considered positive and confirmed later by real time polymerase chain reaction (rPCR). (NCT00367380)
Timeframe: Twenty eight days
| Intervention | days (Mean) |
|---|---|
| Group 1 | 11 |
| Group 2 | 11 |
| Group 3 | 9 |
8 reviews available for chloroquine and Complications, Parasitic Pregnancy
| Article | Year |
|---|---|
Drug treatment and prevention of malaria in pregnancy: a critical review of the guidelines.
Topics: Adult; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artesunate; Chloroquine | 2021 |
Azithromycin-chloroquine and the intermittent preventive treatment of malaria in pregnancy.
Topics: Africa South of the Sahara; Animals; Antimalarials; Azithromycin; Chloroquine; Drug Administration S | 2008 |
Pharmacokinetics of antimalarials in pregnancy: a systematic review.
Topics: Anti-Bacterial Agents; Antimalarials; Artemisinins; Atovaquone; Chloroquine; Drug Therapy, Combinati | 2011 |
Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature.
Topics: Antimalarials; Child; Chloroquine; Databases, Factual; Eye; Eye Diseases; Female; Humans; Hydroxychl | 2011 |
The use of chloroquine during pregnancy.
Topics: Abnormalities, Drug-Induced; Animals; Chloroquine; Female; Humans; Malaria; Pregnancy; Pregnancy Com | 1994 |
Women and malaria--special risks and appropriate control strategy.
Topics: Adolescent; Animals; Child; Child, Preschool; Chloroquine; Developing Countries; Female; Humans; Ind | 1993 |
Clinical malaria in the tropics.
Topics: Africa; Antimalarials; Asia, Southeastern; Chloroquine; Combined Modality Therapy; Drug Resistance; | 1993 |
The safety of antimalarial drugs in pregnancy.
Topics: Animals; Anti-Infective Agents; Antimalarials; Chloroquine; Contraindications; Female; Folic Acid An | 1996 |
33 trials available for chloroquine and Complications, Parasitic Pregnancy
| Article | Year |
|---|---|
Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy.
Topics: Adolescent; Adult; Antimalarials; Area Under Curve; Bayes Theorem; Chloroquine; Dose-Response Relati | 2010 |
Placental but Not Peripheral Plasmodium falciparum Infection During Pregnancy Is Associated With Increased Risk of Malaria in Infancy.
Topics: Chloroquine; Drug Combinations; Female; Follow-Up Studies; Humans; Infant; Logistic Models; Longitud | 2017 |
Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial.
Topics: Adult; Antimalarials; Chloroquine; Drug Combinations; Female; Humans; Infant, Newborn; Malaria; Preg | 2018 |
Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial.
Topics: Adult; Antimalarials; Chloroquine; Drug Combinations; Female; Humans; Infant, Newborn; Malaria; Preg | 2018 |
Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial.
Topics: Adult; Antimalarials; Chloroquine; Drug Combinations; Female; Humans; Infant, Newborn; Malaria; Preg | 2018 |
Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial.
Topics: Adult; Antimalarials; Chloroquine; Drug Combinations; Female; Humans; Infant, Newborn; Malaria; Preg | 2018 |
Sulphadoxine-pyrimethamine plus azithromycin for the prevention of low birthweight in Papua New Guinea: a randomised controlled trial.
Topics: Adult; Antimalarials; Azithromycin; Chloroquine; Drug Combinations; Female; Humans; Infant, Low Birt | 2015 |
Malaria preventive therapy in pregnancy and its potential impact on immunity to malaria in an area of declining transmission.
Topics: Adult; Antibodies, Protozoan; Antimalarials; Azithromycin; Chloroquine; Drug Combinations; Erythrocy | 2015 |
Prevention of malaria during pregnancy: assessing the effect of the distribution of IPTp through the national policy in Benin.
Topics: Adult; Antimalarials; Benin; Chloroquine; Drug Combinations; Female; Health Policy; HIV Infections; | 2011 |
Comparison of intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during pregnancy in Mali.
Topics: Abortion, Spontaneous; Adolescent; Adult; Anemia; Birth Weight; Chemoprevention; Chloroquine; Drug A | 2005 |
Quinine for the treatment of chloroquine-resistant Plasmodium falciparum malaria in pregnant and non-pregnant Sudanese women.
Topics: Adult; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Drug Resistance; Female; Humans | 2005 |
Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethamine used alone or in combination for malaria treatment in pregnancy: a randomised trial.
Topics: Adult; Amodiaquine; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Combinations; Fem | 2006 |
Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women.
Topics: Adolescent; Animals; Antimalarials; Burkina Faso; Child; Child, Preschool; Chloroquine; Drug Adminis | 2007 |
The importance of the period of malarial infection during pregnancy on birth weight in tropical Africa.
Topics: Adolescent; Adult; Africa; Animals; Antimalarials; Birth Weight; Burkina Faso; Chloroquine; Female; | 2007 |
A comparison of sulfadoxine-pyrimethamine with chloroquine and pyrimethamine for prevention of malaria in pregnant Nigerian women.
Topics: Adult; Animals; Antimalarials; Birth Weight; Chloroquine; Drug Combinations; Female; Hematocrit; Hum | 2007 |
Comparison of the therapeutic efficacy of chloroquine and sulphadoxine-pyremethamine in children and pregnant women.
Topics: Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Female; Humans; Malaria, Falciparum | 2007 |
Efficacy of intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine in preventing anaemia in pregnancy among Nigerian women.
Topics: Adolescent; Adult; Anemia; Antimalarials; Chloroquine; Drug Combinations; Female; Humans; Malaria; N | 2008 |
Antibodies to ring-infected erythrocyte surface antigen (Pf155/RESA) protect against P. falciparum parasitemia in highly exposed multigravidas women in Malawi.
Topics: Adult; Amino Acid Sequence; Animals; Antibodies, Protozoan; Antigens, Protozoan; Antigens, Surface; | 1994 |
Testing strategies to increase use of chloroquine chemoprophylaxis during pregnancy in Malaŵi.
Topics: Chemistry, Pharmaceutical; Chloroquine; Effect Modifier, Epidemiologic; Female; Follow-Up Studies; H | 1994 |
The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi.
Topics: Analysis of Variance; Antimalarials; Chi-Square Distribution; Chloroquine; Drug Combinations; Drug T | 1994 |
Marital status and history of a previous child are risk factors in infant mortality.
Topics: Chloroquine; Double-Blind Method; Female; Humans; Infant Mortality; Infant, Newborn; Longitudinal St | 1994 |
Malaria chemosuppression in pregnancy. V. Placenta malarial changes among three different prophylaxis groups.
Topics: Chloroquine; Drug Therapy, Combination; Female; Humans; Malaria; Placenta Diseases; Pregnancy; Pregn | 1993 |
Malaria chemosuppression during pregnancy. IV. Its effects on the newborn's passive malaria immunity.
Topics: Animals; Antibodies, Protozoan; Cesarean Section; Chloroquine; Drug Therapy, Combination; Enzyme-Lin | 1993 |
Malaria chemosuppression in pregnancy. III. Its effects on the maternal malaria immunity.
Topics: Analysis of Variance; Animals; Antibodies, Protozoan; Chloroquine; Drug Therapy, Combination; Enzyme | 1993 |
Malaria chemoprophylaxis compliance in pregnant women: a cost-effectiveness analysis of alternative interventions.
Topics: Anthropology, Cultural; Antimalarials; Chloroquine; Cost-Benefit Analysis; Female; Health Education; | 1993 |
Malaria chemosuppression in pregnancy. I. The effect of chemosuppressive drugs on maternal parasitaemia.
Topics: Adolescent; Adult; Animals; Chloroquine; Drug Combinations; Female; Humans; Malaria, Falciparum; Pla | 1993 |
Malaria chemosuppression in pregnancy. II. Its effect on maternal haemoglobin levels, placental malaria and birth weight.
Topics: Anemia; Birth Weight; Chloroquine; Drug Resistance; Drug Therapy, Combination; Female; Hemoglobins; | 1993 |
Increase of birth weight following chloroquine chemoprophylaxis during the first pregnancy: results of a randomized trial in Cameroon.
Topics: Adolescent; Adult; Animals; Antimalarials; Birth Weight; Cameroon; Chloroquine; Drug Resistance; Ery | 1995 |
Comparability of treatment groups and risk factors for parasitemia at the first antenatal clinic visit in a study of malaria treatment and prevention in pregnancy in rural Malawi.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Female; Humans; Malaria, Falciparum; Malawi; Mefloqui | 1996 |
Malaria parasite infection during pregnancy and at delivery in mother, placenta, and newborn: efficacy of chloroquine and mefloquine in rural Malawi.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Female; Fetal Blood; Humans; Malaria, Falciparum; Mal | 1996 |
Objectives and methodology in a study of malaria treatment and prevention in pregnancy in rural Malawi: The Mangochi Malaria Research Project.
Topics: Antimalarials; Chloroquine; Female; Fetal Death; Follow-Up Studies; Humans; Infant, Low Birth Weight | 1996 |
Effect of chloroquine prophylaxis during pregnancy on maternal haematocrit.
Topics: Anemia; Antimalarials; Chloroquine; Female; Hematocrit; Humans; Malaria, Falciparum; Placenta; Pregn | 1998 |
Randomised trial of alternative malaria chemoprophylaxis strategies among pregnant women in Kigoma, Tanzania: I. Rationale and design.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Therapy, Combinati | 2000 |
Chloroquine prophylaxis, iron/folic-acid supplementation or case management of malaria attacks in primigravidae in western Uganda: effects on congenital malaria and infant haemoglobin concentrations.
Topics: Analysis of Variance; Anemia, Neonatal; Antimalarials; Birth Weight; Chloroquine; Double-Blind Metho | 2000 |
The impact of insecticide-treated bednets on malaria and anaemia in pregnancy in Kassena-Nankana district, Ghana: a randomized controlled trial.
Topics: Analysis of Variance; Anemia; Bedding and Linens; Birth Weight; Chloroquine; Cluster Analysis; Endem | 2001 |
Malaria in infants whose mothers received chemoprophylaxis: response to amodiaquine therapy.
Topics: Administration, Oral; Amodiaquine; Chloroquine; Drug Resistance; Female; Humans; Immunity, Maternall | 1992 |
68 other studies available for chloroquine and Complications, Parasitic Pregnancy
| Article | Year |
|---|---|
Effect of adverse events on non-adherence and study non-completion in malaria chemoprevention during pregnancy trial: A nested case control study.
Topics: Antimalarials; Case-Control Studies; Chemoprevention; Chloroquine; Data Analysis; Drug Combinations; | 2022 |
Quantifying and preventing Plasmodium vivax recurrences in primaquine-untreated pregnant women: An observational and modeling study in Brazil.
Topics: Adolescent; Adult; Antimalarials; Brazil; Case-Control Studies; Child; Chloroquine; Female; Humans; | 2020 |
Prophylactic drugs for malaria: why do we need another one?
Topics: Adult; Antimalarials; Atovaquone; Chemoprevention; Child; Chloroquine; Developed Countries; Developi | 1999 |
[Prevalence of Plasmodium falciparum, anemia and molecular markers of chloroquine and sulfadoxine-pyriméthamine resistance in delivered women in Fana, Mali].
Topics: Adolescent; Adult; Anemia; Chloroquine; Delivery, Obstetric; Drug Combinations; Drug Resistance; Fem | 2013 |
Treatment of pregnant BALB/c mice with sulphadoxine pyrimethamine or chloroquine abrogates Plasmodium berghei induced placental pathology.
Topics: Animals; Antimalarials; Antioxidants; Chloroquine; DNA Fragmentation; Drug Combinations; Female; Lip | 2014 |
Malaria prevention and treatment in pregnancy: survey of current practice among private medical practitioners in Lagos, Nigeria.
Topics: Adult; Antimalarials; Chloroquine; Female; Humans; Malaria; Male; Middle Aged; Nigeria; Practice Pat | 2015 |
Recrudescence of
Topics: Administration, Intravenous; Adult; Antimalarials; Chemoprevention; Chloroquine; Female; Gravidity; | 2017 |
Chloroquine pharmacokinetics in pregnant and nonpregnant women with vivax malaria.
Topics: Acute Disease; Adolescent; Adult; Animals; Antimalarials; Area Under Curve; Chloroquine; Female; Hum | 2008 |
Efficacy of intermittent preventive treatment versus chloroquine prophylaxis to prevent malaria during pregnancy in Benin.
Topics: Adult; Antimalarials; Benin; Chloroquine; Cross-Sectional Studies; Female; Humans; Infant, Low Birth | 2008 |
[Quality of malaria prevention during prenatal consultations in Niakhar (Senegal)].
Topics: Antimalarials; Chloroquine; Cross-Over Studies; Female; Humans; Malaria; Pregnancy; Pregnancy Compli | 2007 |
Sub-microscopic infections and long-term recrudescence of Plasmodium falciparum in Mozambican pregnant women.
Topics: Adult; Animals; Antigens, Protozoan; Antimalarials; Chloroquine; Drug Combinations; Female; Genotype | 2009 |
Congenital Plasmodium vivax malaria mimicking neonatal sepsis: a case report.
Topics: Anti-Bacterial Agents; Antimalarials; Chloroquine; Diagnosis, Differential; Female; Humans; Incident | 2010 |
Perception and practice of malaria prophylaxis in pregnancy among health care providers in Ibadan.
Topics: Antimalarials; Chloroquine; Community Health Services; Drug Combinations; Female; Guideline Adherenc | 2007 |
Utilisation of malaria preventive measures during pregnancy and birth outcomes in Ibadan, Nigeria.
Topics: Adult; Animals; Antimalarials; Attitude to Health; Chloroquine; Drug Combinations; Female; Health Pr | 2011 |
Prophylactic use of antimalarials during pregnancy.
Topics: Antimalarials; Atovaquone; Chemoprevention; Chloroquine; Doxycycline; Drug Combinations; Female; Hum | 2011 |
Patterns of case management and chemoprevention for malaria-in-pregnancy by public and private sector health providers in Enugu state, Nigeria.
Topics: Adult; Antimalarials; Case Management; Chemoprevention; Chloroquine; Drug Combinations; Female; Heal | 2012 |
Standby emergency treatment of malaria in travelers: experience to date and new developments.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Atovaquone; Chloroquine; Dia | 2012 |
Determinants of intermittent preventive treatment of malaria during pregnancy (IPTp) utilization in a rural town in Western Nigeria.
Topics: Adult; Antimalarials; Chemoprevention; Chloroquine; Cities; Cross-Sectional Studies; Drug Administra | 2012 |
New insights into acquisition, boosting, and longevity of immunity to malaria in pregnant women.
Topics: Adult; Antibodies, Protozoan; Antimalarials; Case-Control Studies; Chloroquine; Female; Humans; Immu | 2012 |
Failure of a chloroquine chemoprophylaxis program to adequately prevent malaria during pregnancy in Koupéla District, Burkina Faso.
Topics: Adolescent; Adult; Animals; Antimalarials; Burkina Faso; Chemoprevention; Chloroquine; Cross-Section | 2003 |
Forest malaria in Chhindwara, Madhya Pradesh, central India: a case study in a tribal community.
Topics: Adolescent; Adult; Age Factors; Animals; Anopheles; Antimalarials; Child; Child, Preschool; Chloroqu | 2003 |
Ineffectiveness of chloroquine antenatal prophylaxis in East of Democratic Republic of Congo (RDC).
Topics: Animals; Antimalarials; Chloroquine; Democratic Republic of the Congo; Drug Resistance; Female; Huma | 2003 |
Prevalence of Plasmodium falciparum infection in pregnant women in Gabon.
Topics: Adolescent; Adult; Age Factors; Animals; Chloroquine; Female; Fever; Gabon; Gravidity; Hemoglobin, S | 2003 |
Malaria during pregnancy in a reference centre from the Brazilian Amazon: unexpected increase in the frequency of Plasmodium falciparum infections.
Topics: Adolescent; Adult; Antimalarials; Brazil; Child; Chloroquine; Cross-Sectional Studies; Female; Human | 2004 |
Plasmodium berghei: efficacy and safety of combinations of chloroquine and promethazine in chloroquine resistant infections in gravid mice.
Topics: Animals; Antimalarials; Birth Weight; Chloroquine; Drug Resistance; Drug Therapy, Combination; Femal | 2004 |
Detection of Plasmodium falciparum in pregnancy by laser desorption mass spectrometry.
Topics: Adult; Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Female; Genotype; Hu | 2005 |
Imported malaria in pregnancy: a retrospective study of 18 cases in Marseilles, France.
Topics: Adolescent; Adult; Anemia; Antimalarials; Chloroquine; Female; France; Humans; Hypoglycemia; Malaria | 2005 |
Insight into the early spread of chloroquine-resistant Plasmodium falciparum infections in Papua New Guinea.
Topics: Animals; Antimalarials; Chloroquine; DNA, Protozoan; Drug Resistance; Female; Genes, MDR; Humans; Ma | 2005 |
Prevention of malaria during pregnancy in West Africa: policy change and the power of subregional action.
Topics: Africa, Western; Antimalarials; Chloroquine; Communication Barriers; Drug Combinations; Drug Resista | 2006 |
Therapeutic efficacy of sulphadoxine-pyrimethamine and chloroquine for the treatment of uncomplicated malaria in pregnancy in Burkina Faso.
Topics: Adolescent; Adult; Burkina Faso; Chloroquine; Contraindications; Drug Combinations; Female; Follow-U | 2006 |
A survey of anti-malarial activity during pregnancy, and children's malaria care-seeking behaviour in two Nigerian rural communities.
Topics: Antimalarials; Bedding and Linens; Child, Preschool; Chloroquine; Developing Countries; Female; Huma | 2006 |
Congenital malaria with atypical presentation: a case report from low transmission area in India.
Topics: Animals; Antimalarials; Chloroquine; Female; Humans; India; Infant, Newborn; Infectious Disease Tran | 2007 |
Assessing malaria burden during pregnancy in Mali.
Topics: Adult; Animals; Antimalarials; Chloroquine; Cross-Sectional Studies; Drug Combinations; Female; Huma | 2007 |
Apparent relapse of imported Plasmodium ovale malaria in a pregnant woman.
Topics: Adult; Animals; Antimalarials; Chloroquine; Female; Humans; Malaria; Plasmodium ovale; Pregnancy; Pr | 2007 |
Transfer of chloroquine and desethylchloroquine across the placenta and into milk in Melanesian mothers.
Topics: Adult; Antimalarials; Area Under Curve; Breast Feeding; Chloroquine; Chromatography, High Pressure L | 2008 |
Falciparum malaria, imported into The Netherlands, 1979-1988. II. Clinical features.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Drug Resistance; Female; Humans; Incidence; Malaria, | 1995 |
Perception and utilisation of malaria prophylaxis among pregnant women in Dar es Salaam, Tanzania.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Cross-Sectional Studies; Female; Health Knowledge, At | 1995 |
Antimalarials during pregnancy: a cost-effectiveness analysis.
Topics: Antimalarials; Chloroquine; Cost-Benefit Analysis; Decision Support Techniques; Drug Combinations; F | 1995 |
Malaria chemosuppression during pregnancy. VI. Some epidemiological aspects of malaria in infants.
Topics: Age Factors; Chloroquine; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Huma | 1994 |
[Acute respiratory failure in tropical malaria during pregnancy. Successful treatment using extracorporeal CO2 elimination].
Topics: Acute Disease; Adult; Carbon Dioxide; Cesarean Section; Chloroquine; Drug Therapy, Combination; Extr | 1993 |
Malaria during pregnancy: neonatal morbidity and mortality and the efficacy of chloroquine chemoprophylaxis.
Topics: Birth Weight; Chloroquine; Drug Resistance; Female; Fetal Death; Humans; Infant, Newborn; Malaria, F | 1993 |
Chloroquine-resistant Plasmodium vivax: how common?
Topics: Adult; Animals; Antimalarials; Chloroquine; Drug Resistance; Female; Humans; Malaria, Vivax; Papua N | 1993 |
Sensitivity of Plasmodium falciparum to chloroquine in pregnant women in Zaria, northern Nigeria.
Topics: Animals; Chloroquine; Drug Resistance; Female; Hospitals, General; Humans; In Vitro Techniques; Mala | 1993 |
The effect of malaria and malaria prevention in pregnancy on offspring birthweight, prematurity, and intrauterine growth retardation in rural Malawi.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Female; Fetal Growth Retardation; Humans; Infant, Low | 1996 |
Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Female; Fetal Death; Fever; Humans; Malaria, Falcipar | 1996 |
Evaluation of maternal practices, efficacy, and cost-effectiveness of alternative antimalarial regimens for use in pregnancy: chloroquine and sulfadoxine-pyrimethamine.
Topics: Antimalarials; Chloroquine; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Health Knowled | 1996 |
Resistance to chloroquine therapy in pregnant women with malaria parasitemia.
Topics: Adult; Animals; Antimalarials; Chloroquine; Drug Resistance; Female; Humans; Kenya; Malaria, Falcipa | 1996 |
Severe falciparum malaria with hyperparasitaemia: management without exchange blood transfusion.
Topics: Adolescent; Animals; Antimalarials; Chloroquine; Female; Fetal Death; Humans; Malaria, Falciparum; P | 1996 |
Seasonality, malaria, and impact of prophylaxis in a West African village I. Effect of anemia in pregnancy.
Topics: Adolescent; Adult; Anemia; Antimalarials; Censuses; Chloroquine; Cross-Sectional Studies; Female; He | 1997 |
Seasonality, malaria, and impact of prophylaxis in a West African village. II. Effect on birthweight.
Topics: Adult; Antimalarials; Birth Weight; Chloroquine; Cross-Sectional Studies; Female; Hematocrit; Humans | 1997 |
Chloroquine blood concentrations and malaria prophylaxis in Tanzanian women during the second and third trimesters of pregnancy.
Topics: Adult; Area Under Curve; Chloroquine; Female; Humans; Malaria; Pregnancy; Pregnancy Complications, P | 1997 |
Knowledge and misconceptions about malaria among secondary school students and teachers in Kassala, eastern Sudan.
Topics: Abortifacient Agents; Abortion, Spontaneous; Adolescent; Adult; Age Factors; Antimalarials; Beverage | 1997 |
Studies on malaria during pregnancy in a tribal area of central India (Madhya Pradesh).
Topics: Adult; Antimalarials; Chloroquine; Female; Fever; Hemoglobins; Humans; India; Malaria; Malaria, Falc | 1998 |
Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Adverse Drug Reaction Reporting Systems; | 1998 |
[Prevalence of malaria in Dakar, Senegal. Results of serological survey of pregnant and non-pregnant women].
Topics: Adolescent; Adult; Antibodies, Protozoan; Antimalarials; Chloroquine; Female; Humans; Malaria, Falci | 1997 |
[Evaluation of malaria chemoprevention among 359 pregnant women attending a health center in Dakar].
Topics: Adolescent; Adult; Antimalarials; Chemoprevention; Chloroquine; Female; Humans; Malaria; Maternal He | 1997 |
[Pulmonary manifestations associated with malaria].
Topics: Adult; Anti-Bacterial Agents; Antimalarials; Bronchitis; Child; Chloroquine; Female; Humans; Infant, | 1998 |
[Prevention of malaria].
Topics: Anti-Bacterial Agents; Antimalarials; Chloroquine; Doxycycline; Female; Humans; Malaria; Malaria, Fa | 1999 |
Congenital malaria: diagnosis and therapy.
Topics: Animals; Antimalarials; Chloroquine; District of Columbia; Female; Fever; Humans; Infant; Jaundice; | 2000 |
Epidemiological and control issues related to malaria in pregnancy.
Topics: Africa; Antimalarials; Bedding and Linens; Chloroquine; Drug Resistance; Endemic Diseases; Female; H | 1999 |
Effect of chloroquine prophylaxis on birthweight and malaria parasite load among pregnant women delivering in a regional hospital in Cameroon.
Topics: Adult; Animals; Birth Weight; Cameroon; Chloroquine; Educational Status; Female; Humans; Infant, Low | 2000 |
[Malaria and pregnancy: attitude of health care personnel during prenatal care in Cotonou, Benin].
Topics: Antimalarials; Attitude of Health Personnel; Benin; Chloroquine; Female; Health Policy; Humans; Mala | 2000 |
Acquisition and decay of antibodies to pregnancy-associated variant antigens on the surface of Plasmodium falciparum-infected erythrocytes that protect against placental parasitemia.
Topics: Animals; Antibodies, Protozoan; Antigens, Protozoan; Antimalarials; Cell Adhesion; Chloroquine; Chon | 2001 |
Malaria prophylaxis and the reduction of anemia at childbirth.
Topics: Anemia; Animals; Antimalarials; Birth Weight; Case-Control Studies; Chloroquine; Female; Ghana; Hemo | 2001 |
Plasmodium falciparum pfcrt and pfmdr1 polymorphisms are associated with the pfdhfr N108 pyrimethamine-resistance mutation in isolates from Ghana.
Topics: Adolescent; Adult; Animals; Antimalarials; ATP-Binding Cassette Transporters; Chloroquine; DNA, Prot | 2001 |
Weekly chloroquine prophylaxis and the effect on maternal haemoglobin status at delivery.
Topics: Adult; Anemia; Animals; Antimalarials; Chloroquine; Female; Hemoglobins; Humans; Labor, Obstetric; M | 2002 |
[Malaria and pregnancy].
Topics: Adult; Chloroquine; Female; Fetal Death; Humans; Malaria, Falciparum; Malaria, Vivax; Pregnancy; Pre | 1992 |
Imported malaria in the Bronx: review of 51 cases recorded from 1986 to 1991.
Topics: Adolescent; Adult; Africa, Western; Animals; Antimalarials; Asia, Western; Chi-Square Distribution; | 1992 |